

Clinical trials of evacetrapib

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
evacetrapib vs placebo			
ACCELERATE , 2017 [NCT01687998] n=6038/6054 follow-up:	evacetrapib at adose of 130 mg versus placebo	Patients at a High-Risk for Vascular Outcomes who had at least one of the following conditions: an acute coronary syndrome within the previous 30 to 365 days, cerebrovascular atherosclerotic disease, peripheral vascular arterial disease, or diabetes mellitus with coronary artery disease	Parallel groups double-blind 37 countries

More details and results :

- CEPT inhibition for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q340>
- HDL increasing drugs for cardiovascular prevention in all type of patients at <http://www.trialresultscenter.org/go-Q503>

References

ACCELERATE, 2017:

Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pe Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med 2017;376:1933-1942 [[28514624](#)]